First-Break Psychosis Workup
Comprehensive diagnostic approach to first-episode psychosis—from basic laboratory screening to expanded investigation of atypical presentations
← Back to Blog
Key Takeaway: First-episode psychosis (FEP) demands systematic medical workup before attributing symptoms purely to a primary psychotic disorder. Duration of untreated psychosis (DUP) predicts functional outcomes; early detection and intervention reduce long-term disability. A basic workup addresses common medical causes; expanded investigation rules out rare but critical secondary etiologies.
1. When Is a First-Break Psychosis Workup Indicated?
Defining First-Episode Psychosis (FEP)
First-episode psychosis is the initial presentation of psychotic symptoms in an individual with no prior history of treated psychosis. Key distinctions:
- First psychotic episode—The inaugural presentation of hallucinations, delusions, or thought disorganization meeting psychotic criterion for >1 week
- Prodromal vs. psychotic—FEP begins when frank psychosis emerges, not at earlier subclinical stages
- Age of onset—Median onset 15–35 years; ~75% present by age 40
- Gender patterns—Males typically 2–3 years earlier than females
Why Urgency Matters: Duration of Untreated Psychosis (DUP)
DUP—the interval from symptom onset to initiation of antipsychotic treatment—is one of the strongest predictors of FEP outcome:
3–6 months
Optimal intervention window for best functional outcomes
2+ years
Associated with worse symptom remission, cognitive recovery, and social reintegration
The relationship between DUP and outcome is non-linear but robust: earlier treatment initiation correlates with:
- Higher remission rates of positive symptoms
- Better cognitive preservation and less neurocognitive decline
- Greater likelihood of employment and social functioning at 1–2 years
- Reduced need for hospitalization and crisis interventions
Red Flags vs. Expected Presentation
While primary schizophrenia and bipolar disorder account for ~60% of first psychotic episodes, secondary causes must be excluded:
Red Flags Suggesting Secondary Psychosis
Acute onset (hours to days), age <15 or >40 years, prominent medical symptoms (fever, rash, movement disorder), focal neurological signs, rapid deterioration in consciousness or cognition, previous head trauma, known substance abuse, family history of neurological disease, and abnormal basic labs.
2. Where Does the FEP Workup Typically Occur?
Emergency Department (ED)
Most appropriate for acute, severe presentations with safety concerns. ED physicians perform initial stabilization, vital signs, and basic labs. Psychiatric consultation typically follows; transfer to inpatient psychiatry or crisis stabilization unit arranged based on safety and acuity.
Inpatient Psychiatric Unit
Indicated when active suicidality, homicidality, grave disability, or severe behavioral dyscontrol present. Inpatient teams have capacity for 24/7 monitoring, serial assessments, and rapid diagnostic testing. Ideal for complex medical-psychiatric presentations requiring coordinated workup.
Outpatient Settings & Coordinated Specialty Care (CSC) Programs
For stable patients with less acute presentations, CSC programs (NAVIGATE, OnTrackNY, PREP in California) provide integrated, evidence-based care within 2 weeks of referral. These programs employ:
- Team-based care—Psychiatry, psychology, vocational specialists, peer support
- Rapid access—Goal of medication initiation within 30 days
- Structured medical workup—Coordinated protocols with baseline labs, imaging, and specialist referral as needed
- Functional support—Employment, education, housing, family support from day one
3. The Basic FEP Workup: Essential Laboratory and Clinical Evaluation
Laboratory Tests (First-Line)
Every patient with FEP should undergo the following battery within the first evaluation:
| Test | Purpose | Clinical Yield |
|---|---|---|
| Complete Blood Count (CBC) | Screen for infection, anemia, hematologic malignancy | Identifies WBC elevation (infection), lymphopenia (immunosuppression), or abnormal counts |
| Comprehensive Metabolic Panel (CMP) | Assess renal function, electrolytes, liver function, glucose | Hyponatremia (SIADH), hyperglycemia, renal impairment; baseline before antipsychotics |
| Thyroid Stimulating Hormone (TSH) | Rule out hyperthyroidism or hypothyroidism | Thyroid disease causes >2% of secondary psychosis; TSH elevation common in severe hypothyroidism |
| Urinalysis & Urine Drug Screen (UDS) | Detect substance use (stimulants, hallucinogens, cannabis) | Substance-induced psychosis in ~20–30% of first-episode cases; requires 14–60 day abstinence to resolve |
| Rapid Plasma Reagin (RPR) or VDRL | Screen for neurosyphilis | Treponema pallidum causes neurosyphilis psychosis; requires penicillin therapy if positive + CSF involvement |
| HIV Antibody Test | Detect HIV infection | HIV-associated dementia and opportunistic infections can present as psychosis in <2% of FEP |
| Vitamin B12 & Folate | Identify deficiency-related neuropsychiatric symptoms | B12 deficiency linked to psychosis, delirium, peripheral neuropathy; folate interacts with neurotransmitter synthesis |
| Erythrocyte Sedimentation Rate (ESR) & C-Reactive Protein (CRP) | Nonspecific markers of systemic inflammation | Elevated in infection, autoimmune disease, CNS inflammation; moderately elevated in ~30% of first-episode patients |
Clinical Neurological and Mental Status Examination
Neurological Exam
Systematic assessment for focal deficits
- Cranial nerves (II–XII)
- Motor tone, strength, gait
- Reflexes and Babinski sign
- Cerebellar signs (ataxia, dysmetria)
- Sensory testing
Mental Status Exam
Syndromic and cognitive assessment
- Orientation to person, place, time
- Attention and concentration
- Memory (registration, recall)
- Executive function
- Thought process and content
Structural Brain Imaging
Head CT (non-contrast): Rapid screening tool; rule out acute hemorrhage, mass, midline shift. Standard first-line when MRI unavailable or contraindicated. Sensitivity ~95% for acute stroke, 85% for tumor >1 cm.
Brain MRI (3T preferred): Superior resolution for parenchymal abnormalities, demyelinating disease, small tumors, midbrain lesions. Indicated if:
- First episode with focal neurological signs
- Atypical features (catatonia, seizures, rapid progression)
- Age <20 or >40
- Failed initial antipsychotic response
4. Expanded Workup for Atypical Presentations and Diagnostic Uncertainty
Indications for Expanded Workup
Age <15 or >40, acute onset with fever/rash, focal neurological signs, seizures, rapid deterioration, catatonia, preceding head trauma, family history of autoimmune/neurological disease, failed standard antipsychotic response, or atypical cognitive pattern.
Immunological and Autoimmune Markers
Antinuclear Antibody (ANA)
Systemic lupus erythematosus screening
- Positive in ~40% of SLE; cerebritis causes acute psychosis
- Can precede rash or other systemic features
- Confirmatory: complement levels (C3, C4), anti-dsDNA
Anti-NMDA Receptor Antibody
Auto-immune encephalitis screening
- Psychosis + movement disorder + seizures = encephalitis until proven otherwise
- Test serum & CSF; CSF more sensitive
- Responds to immunotherapy (IVIG, plasmapheresis, rituximab)
Other Autoimmune Markers
Multi-test panel for rare etiologies
- Anti-GABAB, anti-LGI1, anti-Caspr2
- Vasculitis panel (ANCA, anti-GBM)
- Testing via specialized labs (Mayo, Quest immunology)
Metabolic and Genetic Disorders
Ceruloplasmin & Serum Copper
Wilson's disease screening
- Wilson's: hepatic, neuropsychiatric, ophthalmic forms
- Psychosis, tremor, dystonia common presentation age 15–35
- Low ceruloplasmin <20 mg/dL highly specific (high sensitivity too)
Heavy Metals (Lead, Mercury)
Occupational/environmental exposure screening
- Lead encephalopathy: psychosis, ataxia, hypertension
- Mercury: tremor, personality changes, psychosis
- Serum & 24-hour urine, or RBC lead levels
Homocysteine & Methylation
One-carbon metabolism assessment
- Elevated homocysteine linked to psychosis risk
- MTHFR variants may impair B-vitamin metabolism
- Limited clinical yield; research utility
Neurophysiological Testing
Electroencephalography (EEG): Indicated if seizures suspected, catatonia present, or rapid behavioral changes. Sensitivity ~50–70% for seizure detection; may show nonconvulsive status epilepticus or focal abnormalities suggestive of encephalitis.
Continuous EEG monitoring: Recommended if catatonia present to exclude nonconvulsive seizures, which may mimic psychosis.
Lumbar Puncture (CSF Analysis)
Obtained when CNS infection, autoimmune encephalitis, or meningitis suspected. CSF studies include:
- Cell count, protein, glucose
- Gram stain and bacterial culture
- Viral PCR panel (HSV-1/2, EBV, CMV, enterovirus)
- Antibody titers (anti-NMDA, anti-GABAb, anti-LGI1) if available
- CSF-specific IgG index or oligoclonal bands (demyelinating disease)
Advanced Neuroimaging
MRI with Contrast: Gadolinium enhancement reveals blood–brain barrier disruption (infection, inflammation, tumor). Standard for suspected encephalitis, multiple sclerosis, meningitis.
MRI with Specific Sequences:
- Diffusion-weighted imaging (DWI): Acute stroke, encephalitis
- Fluid-attenuated inversion recovery (FLAIR): White matter abnormalities, demyelination
- Susceptibility-weighted imaging (SWI): Microhemorrhages, vascular malformations
Neuropsychological Testing
Formal battery (MMSE, Montreal Cognitive Assessment, or full neuropsych workup) indicated when:
- Cognitive decline is a prominent feature
- Age <20 or >40 (atypical for primary schizophrenia)
- Rapidly progressive course
- Differential diagnosis includes dementia, delirium, or acquired cognitive disorder
5. What Each Test Rules In or Out: Diagnostic Pathology Mapping
Comprehensive Test-Pathology Table
| Diagnostic Test(s) | Rules In | Rules Out / Likelihood Ratio |
|---|---|---|
| TSH, Free T4 | Hyperthyroidism (agitation, tremor, psychosis); Hypothyroidism (depression, apathy, psychosis) | Negative result makes thyroid-induced psychosis unlikely; prevalence ~2–3% of FEP |
| RPR/VDRL | Treponema pallidum infection; if +, CSF testing confirms neurosyphilis (tertiary syphilis psychosis) | Negative (nontreponemal) effectively rules out syphilis as primary etiology; rare (0.5–2% of FEP in high-risk populations) |
| HIV Antibody ± RNA | HIV infection; later stages associated with dementia, opportunistic CNS infection (toxoplasmosis, CMV, PML) | Negative test rules out HIV; psychosis occurs late (CD4 <200 typically); prevalence ~1–3% of FEP depending on population |
| Urine Drug Screen | Recent substance use (amphetamines, cocaine, PCP, LSD, cannabis); substrate of psychosis diagnosis | Negative does not exclude substance-induced if use >48–72 hrs prior; ~20–30% of FEP has concurrent or recent substance use |
| B12, Folate, Methylmalonic acid, Homocysteine | B12 deficiency (pernicious anemia, subacute combined degeneration, neuropsychiatric syndrome) | Low levels associated with psychosis, delirium, neuropathy; ~5–10% of psychiatric populations have deficiency |
| CBC with differential | Infection (elevated WBC), lymphoma (abnormal cells), anemia (contributing to delirium) | Normal CBC reduces likelihood of acute infection or hematologic malignancy; non-specific |
| CMP, glucose | Hyponatremia (SIADH, intoxication), hyperglycemia (metabolic syndrome, diabetes), renal impairment | Baseline assessment before antipsychotics; abnormalities may explain acute mental status change |
| Ceruloplasmin, Slit-lamp exam | Wilson's disease: low ceruloplasmin (<20 mg/dL), Kayser-Fleischer rings on slit-lamp, elevated copper | Wilson's rare (1 in 30,000) but highly treatable; suspect if age <30, movement disorder, liver disease |
| Head CT or MRI | Intracranial mass, hemorrhage, stroke, hydrocephalus, demyelination, focal lesion | Normal imaging does not exclude autoimmune/infectious causes; yields abnormality in ~10–20% of FEP |
| Lumbar Puncture + CSF studies | Meningitis (elevated protein >100, low glucose <40% serum), encephalitis, HSV, autoimmune disease | CSF obtained when fever, stiff neck, seizures, encephalitis suspected; abnormal LP in ~5% of FEP with atypical features |
| Anti-NMDA, Anti-GABAb, Anti-LGI1 (serum/CSF) | Auto-immune encephalitis; psychosis + movement disorder + seizures classic triad | Positive in ~1–3% of psychotic first episodes; CSF more specific than serum; highly treatable with immunotherapy |
| ANA, complement, anti-dsDNA | Systemic lupus erythematosus (SLE) cerebritis as cause of acute psychosis | ANA positive in ~40% of SLE; SLE-induced psychosis rare (<1% of FEP) but more common in younger patients |
| EEG | Nonconvulsive seizures, focal abnormalities (spike-and-wave, slowing), encephalitis pattern | Normal EEG does not exclude seizure disorder; low sensitivity for subclinical seizures; abnormal in ~30–50% of atypical FEP |
| Neuropsych testing | Cognitive impairment pattern: dementia (global decline), delirium (attention/executive deficits), specific deficits | Useful for differential diagnosis; schizophrenia shows relatively preserved memory with executive/processing speed decline |
6. Differential Diagnosis Wheel: Secondary Causes of First-Episode Psychosis
7. Clinical Workup Algorithm: Basic to Expanded Strategy
8. Clinical Pearls & Implementation Tips
Quick-Reference Checklist for Clinical Practice
- Universal screening: CBC, CMP, TSH, UA/UDS, RPR, HIV, B12, ESR/CRP, and neuroimaging in all FEP presentations
- DUP matters: Every month of delay in treatment worsens long-term functional outcomes—prioritize rapid assessment and initiation
- Red flags trigger expansion: Age extremes, acute onset, fever, focal neurology, or family history of neurological disease warrant expanded workup at baseline
- CSF testing: Lumbar puncture is low-risk, high-yield when encephalitis or infection suspected; do not delay if clinical suspicion high
- Antibody panels: Anti-NMDA and other autoimmune markers now widely available; consider in treatment-resistant first episodes or atypical features
- Neuropsych testing: Useful for differential diagnosis at baseline if cognitive impairment prominent; schizophrenia typically preserves memory
- CSC enrollment: Streamlines coordinated workup, speeds antipsychotic initiation, and improves long-term outcomes—refer all eligible FEP patients
- Reassess if no response: 4–6 week non-response to adequate antipsychotic dose should prompt reconsideration of diagnosis and expanded workup
Risk Stratification for Expanded Workup
Low Risk
Age 18–35, insidious onset, positive family history of schizophrenia, normal neuro exam, normal basic labs → proceed with standard FEP care
High Risk
Age extremes, acute presentation, fever/rash, focal signs, seizures, catatonia, rapid cognitive decline → prioritize expanded workup before antipsychotic initiation
When to Consult Specialists
Neurology
Focal neurological signs, seizures, movement disorder
Internal Medicine
Systemic symptoms, metabolic abnormalities, medical complexity
Immunology/Rheumatology
ANA positive, autoimmune encephalitis suspected
Infectious Disease
RPR+, HIV+, CSF abnormalities, fever, meningeal signs
9. Outcomes & Monitoring: Timeline for FEP Care
Week 0: Presentation
Initial assessment, basic workup, safety evaluation. Diagnostic formulation. Antipsychotic initiation if appropriate.
Weeks 1–2: Early Response
Dosage optimization, side effect monitoring. Baseline symptom severity (PANSS or SOPS). Family psychoeducation begins.
Weeks 3–6: Therapeutic Window
Peak therapeutic response should emerge. 20–30% reduction in psychotic symptoms typical. Evaluate need for adjunctive treatment.
Weeks 6–12: Consolidation
Continue antipsychotic monotherapy. Psychotherapy and vocational engagement. Repeat labs (metabolic panel). Cognitive remediation begins.
3–6 Months: Functional Recovery
Return to work/school. Symptom remission target >20% baseline severity. Neuropsych testing for cognitive phenotype. Re-evaluate if limited response.
6–12 Months: Maintenance
Sustained remission, functional integration, family support. Annual labs and metabolic monitoring. Plan for maintenance vs. discontinuation.
References
- Correll CU, Galling B, Pawar A, et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2018;75(6):555–565. doi:10.1001/jamapsychiatry.2018.0623
- Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–193. doi:10.1038/nature09552
- Perkins DO, Lieberman JA, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004;185:18–24. doi:10.1192/bjp.185.1.18
- Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975–983. doi:10.1001/archpsyc.62.9.975
- McGorry PD, Killackey E, Yung AR. Early intervention in psychosis: concepts, evidence and future directions. World J Psychiatry. 2008;7(3):148–156.
- Amminger GP, McGorry PD. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychobiology. 2012;66(2):95–101. doi:10.1159/000338616
- Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353–370. doi:10.1093/schbul/22.2.353
- Mathalon DH, Haselgrove H, Ford JM. Behavioral and cognitive consequences of schizotypy. Schizophr Bull. 2003;29(4):803–817. doi:10.1093/oxfordjournals.schbul.a007046
- Dalmau J, Armangué T, Planagumà J, et al. An Update on Anti-NMDA Receptor Encephalitis for the Clinician: Mechanisms of Disease, Diagnostic Advances, and Immunotherapy. J Neurol Neurosurg Psychiatry. 2019;90(5):552–560. doi:10.1136/jnnp-2018-318913
- Larsen TK, Melle I, Auestad B, et al. Early Detection of Psychosis: Positive Effects on 5-Year Outcome. Psychol Med. 2011;41(6):1461–1469. doi:10.1017/S0033291710001716
- Caroff SN, Mann SC, Campbell EC. Atypical Antipsychotics and the Neuroleptic Malignant Syndrome. Psychiatr Ann. 2000;30(5):314–321.
- Chaudhury S, Bhat PS, Nagarajegowda A, Sharma P, Ohaeri JU. Antipsychotics in First-Episode Psychosis: What Clinicians Need to Know. Curr Psychiatry Rep. 2021;23(2):8. doi:10.1007/s11920-020-01213-7
- Thorup A, Petersen L, Jeppesen P, et al. Integrated Treatment for First-Episode Psychosis in Denmark: Outcome at 5-Year Follow-up. Br J Psychiatry. 2015;207(4):311–316. doi:10.1192/bjp.bp.114.150946
- Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in antipsychotic drug trials: recommendations for the use in clinical practice and research. Acta Psychiatr Scand. 2006;114(6):432–441. doi:10.1111/j.1600-0447.2006.00881.x
- Kane JM, Perkins DO, Simpson GM, et al. Antipsychotic Treatment of Schizophrenia: A Review. J Clin Psychiatry. 2003;64(Suppl 12):5–17.
- McGlashan TH, Addington J, Cannon T. The North American Prodrome Longitudinal Study (NAPLS): Schema, Rationale, and Methods. Schizophr Bull. 2007;33(3):662–672. doi:10.1093/schbul/sbl018
- Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic Dose Reduction in Schizophrenia-How Low Can You Go? Curr Neuropharmacol. 2010;8(3):189–198.
- Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363(9426):2063–2072. doi:10.1016/S0140-6736(04)16458-1
- Norman RMG, Manchanda R, Malla AK, et al. Symptom and Functional Time to Stable Recovery in First-Episode Psychosis. Psychol Med. 2011;41(6):1145–1155. doi:10.1017/S0033291710002011
- Orban C, Schwartze D, König T, Schultze-Lutter F, Riecher-Rössler A, Walther S. Early sensorimotor abnormalities as predictor of psychosis transition. Transl Psychiatry. 2019;9(1):249. doi:10.1038/s41398-019-0581-8